The Technical Analyst
Sutro Biopharma Inc [STRO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Sutro Biopharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
2.34% $3.50
America/New_York / 26 apr 2024 @ 14:44
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 269.22 mill |
| EPS: | -1.780 |
| P/E: | -1.970 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 76.92 mill |
| Avg Daily Volume: | 1.003 mill |
| RATING 2024-04-26 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.970 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.34x |
| Company: PE -1.970 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.00 - 4.00 ( +/- 14.20%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-11 | Srinivasan Venkatesh | Sell | 21 250 | Restricted Stock Unit (RSU) |
| 2024-04-11 | Srinivasan Venkatesh | Buy | 21 250 | Common Stock |
| 2024-04-11 | Srinivasan Venkatesh | Sell | 7 582 | Common Stock |
| 2024-03-05 | Newell William J | Buy | 167 000 | Restricted Stock Units (RSUs) |
| 2024-03-05 | Fitzpatrick Linda A | Buy | 37 100 | Restricted Stock Units (RSUs) |
| INSIDER POWER |
|---|
| 67.79 |
| Last 99 transactions |
| Buy: 2 171 384 | Sell: 404 320 |
Forecast:
16:00 - $3.50
Live Trading Signals (every 1 min)
Forecast
1: 14:53 - $3.50
Forecast 2: 15:43 - $3.49
Forecast 3: 16:00 - $3.50
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.50 (2.34% ) |
| Volume | 0.234 mill |
| Avg. Vol. | 1.003 mill |
| % of Avg. Vol | 23.33 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For STRO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $4.78 | N/A | Active |
|---|
STRO
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Latest Press Releases
2024-04-02 06:18:00 - Press Release
Sutro Biopharma Announces Pricing Of $75 Million Underwritten Offering
South san francisco, calif., april 02, 2024 (globe newswire) -- sutro biopharma, inc. (sutro or the company) (nasdaq: stro), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (adcs), today announced the pricing of an underwritten offering of 14,478,764 shares of its common stock at a price of $5.18 per share. the gross proceeds from this offering are expected to be approximately $75.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by sutro. all of the shares of common stock are being offered by sutro. the offering is expected to close on or about april 4, 2024, subject to the satisfaction of customary closing conditions.
2024-04-02 01:00:00 - Press Release
Ipsen And Sutro Biopharma Announce Exclusive Global Licensing Agreement For An Adc Targeting Solid Tumors
Paris, france; san francisco, u.s., 02 april 2024 - ipsen (euronext: ipn; adr: ipsey) and sutro biopharma (nasdaq: stro, “sutro”, “the company”) today announced an exclusive global licensing agreement for stro-003. stro-003, an antibody-drug conjugate (adc) in the final stages of pre-clinical development, targets the ror1 tumor antigen which is known to be overexpressed in many different cancer types including solid tumors and hematological malignancies.1 the agreement gives ipsen exclusive worldwide rights to develop and commercialize stro-003 and will be the first adc candidate joining ipsen's expanding portfolio.
2024-03-25 16:30:00 - Press Release
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights And Select Anticipated Milestones
- sutro highlighted luveltamab tazevibulin (luvelta) in a january 2024 investor webcast, describing the broad opportunity to address unmet needs in multiple folrΑ-expressing cancers -
2024-02-06 16:05:00 - Press Release
Sutro Biopharma To Participate In Upcoming Investor Conferences
South san francisco, calif., feb. 06, 2024 (globe newswire) -- sutro biopharma, inc. (sutro or the company) (nasdaq: stro), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (adcs), today announced that bill newell, chief executive officer, will participate in three upcoming investor conferences.
2024-01-04 16:05:00 - Press Release
Sutro Biopharma Highlights Potential Multi-cancer Opportunity For Luvelta, A FolrΑ-targeting Adc
Ovarian cancer data supports registration-enabling trial of luvelta for women with platinum-resistant ovarian cancer
Latest News
2024-04-05 18:31:56 - Seeking Alpha
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
2024-03-25 19:31:04 - Zacks Investment Research
Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates
Sutro Biopharma, Inc. (STRO) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of a loss of $0.82 per share. This compares to loss of $0.61 per share a year ago.
2024-03-21 10:56:15 - Zacks Investment Research
Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock Now
Sutro Biopharma (STRO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
2024-02-28 05:41:04 - Zacks Investment Research
Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?
Sutro Biopharma, Inc. (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2024-02-06 16:05:00 - GlobeNewsWire
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in three upcoming investor conferences.
2023-12-14 16:05:00 - GlobeNewsWire
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host an investor webcast to highlight the broad opportunity for its foundational ADC program, Luveltamab tazevibulin (luvelta), a novel folate receptor-α (FolRα) targeting ADC which has now shown clinical activity in three different tumor types to date. The live webcast will be held on Thursday, January 4, 2024, starting at 1:30 p.m. PT / 4:30 p.m. ET featuring presentations by members of Sutro's senior management team and external key opinion leaders in oncology; and concluding with a Q&A session.
2023-11-13 09:47:18 - Zacks Investment Research
Why Sutro Biopharma (STRO) Might Surprise This Earnings Season
Sutro Biopharma (STRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
2023-10-09 09:48:33 - Seeking Alpha
Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching
Sutro Biopharma is advancing its lead candidate, luvelta, for the treatment of various types of cancer, with a focus on ovarian and endometrial cancers. The company will present results from a phase 1b study using luvelta to treat endometrial cancer at the ESMO Congress 2023, which could indicate its potential for ovarian cancer treatment. Sutro Biopharma has enough cash to fund its operations until the first half of 2025, with cash and investments of $358.3 million as of June 30, 2023.
2023-08-30 08:00:00 - GlobeNewsWire
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences.
2023-08-10 19:46:32 - Zacks Investment Research
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.55 per share a year ago.